undamentalytics Newsletter
Sign in

Celularity Inc income statement

In fiscal 2025, Celularity Inc reported revenue of $26.6m, down 51.0% on the year before, operating income of −$61.3m (a -230.9% margin) and net income of −$91.7m, or −$3.59 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue14211823542719
Cost of revenue———16152015
Gross profit912−273964
Research and development53887830171513
Selling, general and administrative31716651595138
Operating income−152−109−26−192−38−61−49
Income before tax−213−10014−196−58−92−46
Income tax−5000—0—
Net income−208−10014−196−58−92−46
Diluted EPS−$113.10−$14.90$0.95−$11.02−$2.64−$3.59−$1.60
Diluted shares (average)2m7m15m18m22m26m29m
EBITDA−144−100−16−183−30−54−43

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CELU vs CTMXCELU vs SCYXCELU vs PRQR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Celularity Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Celularity Inc.